|
US4440859A
(en)
|
1977-05-27 |
1984-04-03 |
The Regents Of The University Of California |
Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
|
|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
|
YU44186B
(en)
|
1978-12-22 |
1990-04-30 |
Biogen Nv |
Process for obtaining recombinant dnk molecules
|
|
US4530901A
(en)
|
1980-01-08 |
1985-07-23 |
Biogen N.V. |
Recombinant DNA molecules and their use in producing human interferon-like polypeptides
|
|
US4342566A
(en)
|
1980-02-22 |
1982-08-03 |
Scripps Clinic & Research Foundation |
Solid phase anti-C3 assay for detection of immune complexes
|
|
US4678751A
(en)
|
1981-09-25 |
1987-07-07 |
Genentech, Inc. |
Hybrid human leukocyte interferons
|
|
US4766075A
(en)
|
1982-07-14 |
1988-08-23 |
Genentech, Inc. |
Human tissue plasminogen activator
|
|
US4582800A
(en)
|
1982-07-12 |
1986-04-15 |
Hoffmann-La Roche Inc. |
Novel vectors and method for controlling interferon expression
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4757006A
(en)
|
1983-10-28 |
1988-07-12 |
Genetics Institute, Inc. |
Human factor VIII:C gene and recombinant methods for production
|
|
US4677063A
(en)
|
1985-05-02 |
1987-06-30 |
Cetus Corporation |
Human tumor necrosis factor
|
|
US4810648A
(en)
|
1986-01-08 |
1989-03-07 |
Rhone Poulenc Agrochimie |
Haloarylnitrile degrading gene, its use, and cells containing the gene
|
|
US4897445A
(en)
|
1986-06-27 |
1990-01-30 |
The Administrators Of The Tulane Educational Fund |
Method for synthesizing a peptide containing a non-peptide bond
|
|
CA2163032C
(en)
|
1993-06-03 |
2001-02-06 |
John Landon |
Antibody fragments in therapy
|
|
AUPM322393A0
(en)
|
1993-12-24 |
1994-01-27 |
Austin Research Institute, The |
Mucin carbohydrate compounds and their use in immunotherapy
|
|
US5977300A
(en)
|
1994-06-03 |
1999-11-02 |
Ludwig Institute Of Cancer Research |
Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
|
|
US6805861B2
(en)
|
1996-01-17 |
2004-10-19 |
Imperial College Innovations Limited |
Immunotherapy using cytotoxic T lymphocytes (CTL)
|
|
US5849589A
(en)
|
1996-03-11 |
1998-12-15 |
Duke University |
Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
|
|
US6406705B1
(en)
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
|
EP1266221A1
(en)
|
2000-01-20 |
2002-12-18 |
Ludwig Institute For Cancer Research |
Mage antigenic peptides which bind hla-b35 and hla-b44
|
|
US20040191260A1
(en)
|
2003-03-26 |
2004-09-30 |
Technion Research & Development Foundation Ltd. |
Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
|
|
EP1294748B1
(en)
|
2000-03-27 |
2010-06-30 |
Technion Research and Development of Foundation, Ltd. |
Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
|
|
EP2322228B1
(en)
|
2000-06-05 |
2018-01-10 |
Altor BioScience Corporation |
T cell receptor fusion proteins and conjugates and methods of use thereof
|
|
US20030171275A1
(en)
|
2000-12-20 |
2003-09-11 |
Baughn Mariah R. |
Transporters and ion channels
|
|
US20030087245A1
(en)
|
2001-01-24 |
2003-05-08 |
Eos Biotechnology, Inc. |
Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer
|
|
AU2002322280A1
(en)
|
2001-06-21 |
2003-01-21 |
Millennium Pharmaceuticals, Inc. |
Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
|
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
|
AU2003216341A1
(en)
|
2002-02-20 |
2003-09-09 |
Dyax Corporation |
Mhc-peptide complex binding ligands
|
|
US7311914B2
(en)
|
2002-08-13 |
2007-12-25 |
Ludwig Institute For Cancer Research |
MAGE-A4 antigenic peptides and uses thereof
|
|
AU2003271904B2
(en)
|
2002-10-09 |
2009-03-05 |
Adaptimmune Limited |
Single chain recombinant T cell receptors
|
|
EP2048159B1
(en)
|
2002-11-09 |
2014-01-01 |
Immunocore Ltd. |
T cell receptor display
|
|
GB0304068D0
(en)
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
|
US7348007B2
(en)
|
2004-02-09 |
2008-03-25 |
Ludwig Institute For Cancer Research |
Mage C2 antigenic peptides and uses thereof
|
|
US7883858B2
(en)
|
2005-01-27 |
2011-02-08 |
Institute For Systems Biology |
Methods for identifying and monitoring drug side effects
|
|
DE602005020046D1
(de)
|
2005-09-05 |
2010-04-29 |
Immatics Biotechnologies Gmbh |
Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
|
|
US8399201B2
(en)
|
2005-10-31 |
2013-03-19 |
Janssen Pharmaceutica N.V. |
Polypeptide complex of TRPM8 and calmodulin and its uses thereof
|
|
US20090263574A1
(en)
|
2008-04-21 |
2009-10-22 |
Quinn Daniel E |
Method of restoring an article
|
|
WO2010037395A2
(en)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
US9840695B2
(en)
|
2009-04-28 |
2017-12-12 |
Agriculture Victoria Services Pty Ltd |
Plant technology
|
|
GB201006360D0
(en)
|
2010-04-16 |
2010-06-02 |
Immatics Biotechnologies Gmbh |
Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
|
|
US9115402B2
(en)
|
2010-05-14 |
2015-08-25 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods of identifying tumor specific neoantigens
|
|
EP2632955A1
(en)
|
2010-10-26 |
2013-09-04 |
Technion Research & Development Foundation Ltd. |
Antibodies which bind soluble t-cell receptor ligands
|
|
US20130303826A1
(en)
|
2011-01-11 |
2013-11-14 |
University Health Network |
Prognostic signature for oral squamous cell carcinoma
|
|
WO2013057586A1
(en)
|
2011-10-19 |
2013-04-25 |
Oslo Universitetssykehus Hf |
Compositions and methods for producing soluble t - cell receptors
|
|
WO2014071978A1
(en)
|
2012-11-08 |
2014-05-15 |
Roche Diagnostics Gmbh |
Nucleic acids encoding chimeric polypeptides for library screening
|
|
EP2808392A1
(en)
|
2013-05-28 |
2014-12-03 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Aptamers and use of the aptamers in the diagnosis and treatment of cancer
|
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
GB201505305D0
(en)
*
|
2015-03-27 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel Peptides and combination of peptides for use in immunotherapy against various tumors
|
|
EP3297652A4
(en)
|
2015-05-19 |
2019-06-05 |
La Jolla Institute for Allergy and Immunology |
HUMAN APOB100 EPITOPES, METHOD AND USES FOR MODULATING INFLAMMATORY REACTIONS AND TREATING UNWANTED CARDIOVASCULAR EVENTS, DISEASES AND ATHEROSCLEROSIS
|
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
|
GB201520541D0
(en)
|
2015-11-23 |
2016-01-06 |
Immunocore Ltd & Adaptimmune Ltd |
Peptides
|
|
KR20190057345A
(ko)
*
|
2016-09-21 |
2019-05-28 |
아말 테라퓨틱스 에스에이 |
암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체
|
|
BR112019018307A2
(pt)
*
|
2017-03-03 |
2020-03-31 |
Treos Bio Zrt |
Plataforma para identificação de peptídeos imunogênicos baseada em população
|
|
TW201841934A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於治療癌症免疫治療的新穎肽及其肽組合物
|
|
TW201841937A
(zh)
|
2017-04-10 |
2018-12-01 |
德商英麥提克生物技術股份有限公司 |
用於白血病和其他癌症免疫治療的新穎肽和肽組合物
|
|
WO2019007974A1
(en)
|
2017-07-07 |
2019-01-10 |
Immatics Biotechnologies Gmbh |
NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|